文献速递术前评估与围术期医学疼痛医学

低剂量丁丙诺啡输注预防瑞芬太尼麻醉下大肺手术后痛觉过敏

Low-dose buprenorphine infusion to prevent postoperative hyperalgesia in patients undergoing major lung surgery and remifentanil infusion: a double-blind, randomized, active-controlled trial.
PubMed 文献 · Br J Anaesth · 2017-01-01

丁丙诺啡组术后切口周围痛觉过敏/异常性疼痛更少,拔管至首次吗啡补救剂量时间更长(18 vs 9 min,P=0.002),但3个月时两组无差异。

要点

  • 低剂量丁丙诺啡输注可减少大肺手术后切口周围继发性痛觉过敏。
  • 丁丙诺啡组拔管至首次吗啡补救时间18 min,对吗啡组9 min(P=0.002)。
  • 术后3个月两组神经病理性疼痛无差异,无长期获益。

核心结论

  • 低剂量丁丙诺啡输注可预防手术切口周围继发性痛觉过敏,但3个月随访无长期疗效。

研究设计与样本

  • 患者随机接受丁丙诺啡静脉输注(25 μg h-1持续24 h)或等效剂量吗啡围术期输注。

主要发现

  • 对照组术后切口周围明显痛觉过敏或异常性疼痛的患者多于丁丙诺啡组。
  • 丁丙诺啡组拔管至首次吗啡补救剂量的平均时间为18 min,吗啡组为9 min(P=0.002)。
  • 术后30 min,吗啡组首次镇痛补救剂量的风险比高于丁丙诺啡组(P=0.009)。
  • 术后3个月两组神经病理性疼痛无差异。

关键数值与推荐

  • 丁丙诺啡剂量为25 μg h-1静脉输注24 h;对照为等效镇痛剂量吗啡。
  • 主要结局为术后第一天点状痛觉过敏的存在与范围。

临床怎么用

  • 对接受瑞芬太尼输注的大肺手术患者,围术期低剂量丁丙诺啡输注可能减少术后继发性痛觉过敏和早期阿片需求。
  • 该方案对术后3个月神经病理性疼痛无预防作用,不应以长期镇痛为由使用。

局限性

  • 仅评估术后1天痛觉过敏及1、3个月神经病理性疼痛,缺乏更长期随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postoperative secondary hyperalgesia arises from central sensitization due to pain pathways facilitation and/or acute opioid exposure. The latter is also known as opioid-induced hyperalgesia (OIH). Remifentanil, a potent μ-opioid agonist, reportedly induces postoperative hyperalgesia and increases postoperative pain scores and opioid consumption. The pathophysiology underlying secondary hyperalgesia involves N-methyl-D-aspartate (NMDA)-mediated pain pathways. In this study, we investigated whether perioperatively infusing low-dose buprenorphine, an opioid with anti-NMDA activity, in patients receiving remifentanil infusion prevents postoperative secondary hyperalgesia. METHODS: Sixty-four patients, undergoing remifentanil infusion during general anaesthesia and major lung surgery, were randomly assigned to receive either buprenorphine i.v. infusion (25 μg h-1 for 24 h) or morphine (equianalgesic dose) perioperatively. The presence and extent of punctuate hyperalgesia were assessed one day postoperatively. Secondary outcome variables included postoperative pain scores, opioid consumption and postoperative neuropathic pain assessed one and three months postoperatively. RESULTS: A distinct area of hyperalgesia or allodynia around the surgical incision was found in more patients in the control group than in the treated group. Mean time from extubation to first morphine rescue dose was twice as long in the buprenorphine-treated group than in the morphine-treated group: 18 vs 9 min (P=0.002). At 30 min postoperatively, patients receiving morphine had a higher hazard ratio for the first analgesic rescue dose than those treated with buprenorphine (P=0.009). At three months, no differences between groups were noted. CONCLUSIONS: Low-dose buprenorphine infusion prevents the development of secondary hyperalgesia around the surgical incision but shows no long-term efficacy at three months follow-up.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Mercieri M, Palmisani S, De Blasi RA, et al. Low-dose buprenorphine infusion to prevent postoperative hyperalgesia in patients undergoing major lung surgery and remifentanil infusion: a double-blind, randomized, active-controlled trial. Br J Anaesth. 2017. PMID: 29121294. doi:10.1093/bja/aex174

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。